- Home
- COYA vs ANVS Comparison
COYA vs ANVS Comparison
Compare COYA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | ANVS |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 111.3M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COYA | ANVS |
|---|---|---|
| Price | $5.25 | $3.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $15.80 | $13.50 |
| AVG Volume (30 Days) | 225.7K | ★ 614.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,987,706.00 | N/A |
| Revenue This Year | $69.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $1.11 |
| 52 Week High | $8.29 | $5.57 |
Technical Indicators
Market Signals| Indicator | COYA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 54.68 |
| Support Level | $5.29 | $3.26 |
| Resistance Level | $5.93 | $3.72 |
| Average True Range (ATR) | 0.40 | 0.26 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 10.26 | 80.25 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.